Background: Studies on 24-hour growth hormone (GH) secretion are rare. The influences of sex, age, and adiposity are well recognized but generally derived from specific, selected subject groups, not spanning sexes, many age decades, and a range of body weights. Objective: Our goal was to investigate GH dynamics in a group of 130 healthy adult subjects, both men and women, across 5 age decades as well as a 2.5-fold range of body mass index (BMI) values. Methods: GH was measured by a sensitive immunofluorometric assay. Secretion parameters were quantified by automated deconvolution and relative pattern randomness by approximate entropy (ApEn). Results: The median age was 40 years (range 20-77). The median BMI was 26 (range 18.3-49.8). Pulsatile 24-hour GH secretion was negatively correlated with age (p = 0.002) and BMI (p < 0.0001). Basal GH secretion negatively correlated with BMI (p = 0.003) but not with age. The sex- dependent GH secretion (greater in women) was no longer detectable after 50 years of age. Insulin-like growth factor (IGF)-1 levels were lower in women over 50 years of age compared with men of a similar age. ApEn showed an age-related increase in both sexes and was higher in premenopausal and postmenopausal women than in men of comparable age (p < 0.0001). A single fasting GH measurement is not informative of 24-hour GH secretion. Conclusions: BMI dominates the negative regulation of 24-hour GH secretion across 5 decades of age in this up till now largest cohort of healthy adults who underwent 24-hour blood sampling. Sex also impacts GH secretion before the age of 50 years as well as its regularity at all ages. Differences in serum IGF-1 partly depend on the pre- or postmenopausal state. Finally, a single GH measurement is not informative of 24-hour GH secretion.

Keywords:
Deconvolution, Approximate entropy, Secretion, Sex, Human, Age, Obesity, Body mass index
1.
Giustina A, Veldhuis JD: Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-797.
2.
Roelfsema F, Biermasz NR, Veldhuis JD: Pulsatile, nyctohemeral and entropic characteristics of GH secretion in adult GH-deficient patients: selectively decreased pulsatile release and increased secretory disorderliness with preservation of diurnal timing and gender distinctions. Clin Endocrinol (Oxf) 2002;56:79-87.
3.
Van Dam EW, Roelfsema F, Helmerhorst FH, Frölich M, Meinders AE, Veldhuis JD, Pijl H: Low amplitude and disorderly spontaneous growth hormone release in obese women with or without polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:4225-4230.
4.
Van den Berg G, Frölich M, Veldhuis JD, Roelfsema F: Growth hormone secretion in recently operated acromegalic patients. J Clin Endocrinol Metab 1994;79:1706-1715.
5.
Van den Berg G, Veldhuis JD, Frölich M, Roelfsema F: An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 1996;81:2460-2467.
6.
Aziz NA, Pijl H, Frölich M, Schröder-van der Elst JP, van der Bent C, Roelfsema F, Roos RA: Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease. Eur J Neurol 2010;17:280-288.
7.
Aziz NA, Pijl H, Frölich M, Roelfsema F, Roos RA: Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson's disease. J Neuroendocrinol 2011;23:519-524.
8.
Donjacour CE, Aziz NA, Roelfsema F, Frölich M, Overeem S, Lammers GJ, Pijl H: Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. Am J Physiol Endocrinol Metab 2011;300:E1069-E1075.
9.
Kok P, Buijs MM, Kok SW, Van Ierssel IH, Frölich M, Roelfsema F, Voshol PJ, Meinders AE, Pijl H: Acipimox enhances spontaneous growth hormone secretion in obese women. Am J Physiol Regul Integr Comp Physiol 2004;286:R693-R698.
10.
Van der Klaauw AA, Pereira AM, van Thiel SW, Smit JW, Corssmit EP, Biermasz NR, Frölich M, Iranmanesh A, Veldhuis JD, Roelfsema F, Romijn JA: GH deficiency in patients irradiated for acromegaly: significance of GH stimulatory tests in relation to the 24 h GH secretion. Eur J Endocrinol 2006;154:851-858.
11.
Silbergeld A, Jaber L, Lilos P, Laron Z: A comparison of IGF-I levels measured by two commercially available radioimmunoassays. Acta Endocrinol (Copenh) 1988;119:333-338.
12.
Keenan DM, Chattopadhyay S, Veldhuis JD: Composite model of time-varying appearance and disappearance of neurohormone pulse signals in blood. J Theor Biol 2005;236:242-255.
13.
Keenan DM, Roelfsema F, Biermasz N, Veldhuis JD: Physiological control of pituitary hormone secretory-burst mass, frequency, and waveform: a statistical formulation and analysis. Am J Physiol Regul Integr Comp Physiol 2003;285:R664-R673.
14.
Liu PY, Keenan DM, Kok P, Padmanabhan V, O'Byrne KT, Veldhuis JD: Sensitivity and specificity of pulse detection using a new deconvolution method. Am J Physiol Endocrinol Metab 2009;297:E538-E544.
15.
Pincus SM: Irregularity and asynchrony in biologic network signals. Methods Enzymol 2000;321:149-182.
16.
Pincus SM, Keefe DL: Quantification of hormone pulsatility via an approximate entropy algorithm. Am J Physiol 1992;262:E741-E754.
17.
Pincus SM: Approximate entropy as a measure of system complexity. Proc Natl Acad Sci USA 1991;88:2297-2301.
18.
Veldhuis JD, Roelfsema F, Keenan DM, Pincus S: Gender, age, body mass index, and IGF-I individually and jointly determine distinct GH dynamics: analyses in one hundred healthy adults. J Clin Endocrinol Metab 2011;96:115-121.
19.
Iranmanesh A, Lizarralde G, Veldhuis JD: Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991;73:1081-1088.
20.
Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL, Thorner MO: Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51-58.
21.
Zadik Z, Chalew SA, McCarter RJ Jr, Meistas M, Kowarski AA: The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 1985;60:513-516.
22.
Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA, Bain RP: Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest 1981;67:1361-1369.
23.
Huang L, Steyn FJ, Tan HY, Xie TY, Veldhuis JD, Ngo ST, Chen C: The decline in pulsatile GH secretion throughout early adulthood in mice is exacerbated by dietary-induced weight gain. Endocrinology 2012;153:4380-4388.
24.
Takahashi S, Gottschall PE, Quigley KL, Goya RG, Meites J: Growth hormone secretory patterns in young, middle-aged and old female rats. Neuroendocrinology 1987;46:137-142.
25.
Sonntag WE, Steger RW, Forman LJ, Meites J: Decreased pulsatile release of growth hormone in old male rats. Endocrinology 1980;107:1875-1879.
26.
Veldhuis JD, Iranmanesh A, Lizarralde G, Urban RJ: Combined deficits in the somatotropic and gonadotropic axes in healthy aging men: an appraisal of neuroendocrine mechanisms by deconvolution analysis. Neurobiol Aging 1994;15:509-517.
27.
Frutos MG, Cacicedo L, Mendez CF, Vicent D, Gonzalez M, Sanchez-Franco F: Pituitary alterations involved in the decline of growth hormone gene expression in the pituitary of aging rats. J Gerontol A Biol Sci Med Sci 2007;62:585-597.
28.
Velasco B, Cacicedo L, Escalada J, Lopez-Fernandez J, Sanchez-Franco F: Growth hormone gene expression and secretion in aging rats is age dependent and not age-associated weight increase related. Endocrinology 1998;139:1314-1320.
29.
Console GM, Gomez Dumm CL, Goya RG: Impact of aging on the morphology and function of the somatotroph cell population in rats. Mech Ageing Dev 1993;70:45-51.
30.
Veldhuis JD, Weltman JY, Weltman AL, Iranmanesh A, Müller EE, Bowers CY: Age and secretagogue type jointly determine dynamic growth hormone responses to exogenous insulin-like growth factor-negative feedback in healthy men. J Clin Endocrinol Metab 2004;89:5542-5548.
31.
Müller EE, Cella SG, Parenti M, Deghenghi R, Locatelli V, De Gennaro Colonna V, Torsello A, Cocchi D: Somatotropic dysregulation in old mammals. Horm Res 1995;43:39-45.
32.
Walker RF, Yang SW, Bercu BB: Robust growth hormone (GH) secretion in aged female rats co-administered GH-releasing hexapeptide (GHRP-6) and GH-releasing hormone (GHRH). Life Sci 1991;49:1499-1504.
33.
Clasey JL, Weltman A, Patrie J, Weltman JY, Pezzoli S, Bouchard C, Thorner MO, Hartman ML: Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J Clin Endocrinol Metab 2001;86:3845-3852.
34.
Makimura H, Stanley T, Mun D, You SM, Grinspoon S: The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J Clin Endocrinol Metab 2008;93:4254-4260.
35.
Pijl H, Langendonk JG, Burggraaf J, Frölich M, Cohen AF, Veldhuis JD, Meinders AE: Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J Clin Endocrinol Metab 2001;86:5509-5515.
36.
Tanaka K, Inoue S, Numata K, Okazaki H, Nakamura S, Takamura Y: Very-low-calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-dopa in obesity. Metabolism 1990;39:892-896.
37.
Williams T, Berelowitz M, Joffe SN, Thorner MO, Rivier J, Vale W, Frohman LA: Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. N Engl J Med 1984;311:1403-1407.
38.
Rasmussen MH, Hvidberg A, Juul A, Main KM, Gotfredsen A, Skakkebaek NE, Hilsted J, Skakkebae NE: Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab 1995;80:1407-1415.
39.
De Schepper JA, Smitz JP, Zhou XL, Louis O, Velkeniers BE, Vanhaelst L: Cafeteria diet-induced obesity is associated with a low spontaneous growth hormone secretion and normal plasma insulin-like growth factor-I concentrations. Growth Horm IGF Res 1998;8:397-401.
40.
Casanueva FF, Dieguez C: Interaction between body composition, leptin and growth hormone status. Baillieres Clin Endocrinol Metab 1998;12:297-314.
41.
Tannenbaum GS, Epelbaum J, Videau C, Dubuis JM: Sex-related alterations in hypothalamic growth hormone-releasing hormone mRNA- but not somatostatin mRNA-expressing cells in genetically obese Zucker rats. Neuroendocrinology 1996;64:186-193.
42.
Cattaneo L, De Gennaro Colonna V, Zoli M, Müller EE, Cocchi D: Hypothalamo-pituitary-IGF-1 axis in female rats made obese by overfeeding. Life Sci 1997;61:881-889.
43.
Casanueva FF, Villanueva L, Dieguez C, Diaz Y, Cabranes JA, Szoke B, Scanlon MF, Schally AV, Fernandez-Cruz A: Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. J Clin Endocrinol Metab 1987;65:634-642.
44.
Imaki T, Shibasaki T, Shizume K, Masuda A, Hotta M, Kiyosawa Y, Jibiki K, Demura H, Tsushima T, Ling N: The effect of free fatty acids on growth hormone (GH)-releasing hormone-mediated GH secretion in man. J Clin Endocrinol Metab 1985;60:290-293.
45.
Cordido F, Peino R, Penalva A, Alvarez CV, Casanueva FF, Dieguez C: Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. J Clin Endocrinol Metab 1996;81:914-918.
46.
Yamashita S, Melmed S: Insulin regulation of rat growth hormone gene transcription. J Clin Invest 1986;78:1008-1014.
47.
Luque RM, Kineman RD: Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology 2006;147:2754-2763.
48.
Lanzi R, Pontiroli AE: Growth hormone treatment for the elderly? Aging (Milano) 1992;4:179-181.
49.
De Marinis L, Bianchi A, Mancini A, Gentilella R, Perrelli M, Giampietro A, Porcelli T, Tilaro L, Fusco A, Valle D, Tacchino RM: Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition. J Clin Endocrinol Metab 2004;89:174-180.
50.
Eskes SA, Tomasoa NB, Endert E, Geskus RB, Fliers E, Wiersinga WM: Establishment of reference values for endocrine tests. Part VII. Growth hormone deficiency. Neth J Med 2009;67:127-133.
51.
O'Connor KG, Tobin JD, Harman SM, Plato CC, Roy TA, Sherman SS, Blackman MR: Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men. J Gerontol A Biol Sci Med Sci 1998;53:M176-M182.
52.
Schoen RE, Schragin J, Weissfeld JL, Thaete FL, Evans RW, Rosen CJ, Kuller LH: Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women. Cancer Epidemiol Biomarkers Prev 2002;11:581-586.
53.
Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, Körner A, Obermayer-Pietsch B, Hübener C, Dahlgren J, Frystyk J, Pfeiffer AF, Doering A, Bielohuby M, Wallaschofski H, Arafat AM: Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 2014;99:1712-1721.
54.
Frystyk J, Hussain M, Skjaerbaek C, Schmitz O, Christiansen JS, Froesch ER, Orskov H: Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs saline. Am J Physiol 1997;273:E507-E513.
55.
Yamashita S, Melmed S: Insulin-like growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells. J Clin Invest 1987;79:449-452.
56.
Roelfsema F, Pereira AM, Adriaanse R, Endert E, Fliers E, Romijn JA, Veldhuis JD: Thyrotropin secretion in mild and severe primary hypothyroidism is distinguished by amplified burst mass and basal secretion with increased spikiness and approximate entropy. J Clin Endocrinol Metab 2010;95:928-934.
57.
Veldhuis JD, Keenan DM, Mielke K, Miles JM, Bowers CY: Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy. Eur J Endocrinol 2005;153:577-586.
58.
Veldhuis JD, Straume M, Iranmanesh A, Mulligan T, Jaffe C, Barkan A, Johnson ML, Pincus S: Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans. Am J Physiol Regul Integr Comp Physiol 2001;280:R721-R729.
59.
Veldhuis JD, Keenan DM, Bailey JN, Adeniji A, Miles JM, Paulo R, Cosma M, Soares-Welch C: Estradiol supplementation in postmenopausal women attenuates suppression of pulsatile growth hormone secretion by recombinant human insulin-like growth factor type I. J Clin Endocrinol Metab 2008;93:4471-4478.
60.
Veldhuis JD, Roelfsema F, Iranmanesh A, Carroll BJ, Keenan DM, Pincus SM: Basal, pulsatile, entropic (patterned), and spiky (staccato-like) properties of ACTH secretion: impact of age, gender, and body mass index. J Clin Endocrinol Metab 2009;94:4045-4052.
61.
Roelfsema F, Pijl H, Keenan DM, Veldhuis JD: Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS One 2012;7:e31305.
62.
Roelfsema F, Pijl H, Kok P, Endert E, Fliers E, Biermasz NR, Pereira AM, Veldhuis JD: Thyrotropin secretion in healthy subjects is robust and independent of age and gender, and only weakly dependent on body mass index. J Clin Endocrinol Metab 2014;99:570-578.
63.
Pincus SM, Mulligan T, Iranmanesh A, Gheor- ghiu S, Godschalk M, Veldhuis JD: Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. Proc Natl Acad Sci USA 1996;93:14100-14105.
64.
Pincus SM, Veldhuis JD, Mulligan T, Iranmanesh A, Evans WS: Effects of age on the irregularity of LH and FSH serum concentrations in women and men. Am J Physiol 1997;273:E989-E995.
65.
Veldhuis JD, Hudson SB, Erickson D, Bailey JN, Reynolds GA, Bowers CY: Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women. Am J Physiol Endocrinol Metab 2009;297:E367-E374.
66.
Hudson SB, Schroeder DR, Bailey JN, Mielke KL, Erickson D, Miles JM, Bowers CY, Veldhuis JD: Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp. J Clin Endocrinol Metab 2010;95:353-360.
67.
Kok P, Paulo RC, Cosma M, Mielke KL, Miles JM, Bowers CY, Veldhuis JD: Estrogen supplementation selectively enhances hypothalamo-pituitary sensitivity to ghrelin in postmenopausal women. J Clin Endocrinol Metab 2008;93:4020-4026.
68.
Tannenbaum GS, Gurd W, Lapointe M, Pollak M: Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 1992;130:3395-3401.
69.
Appelman-Dijkstra NM, Claessen KM, Roelfsema F, Pereira AM, Biermasz NR: Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol 2013;169:R1-R14.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.